BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 11982724)

  • 1. Hepatitis C advances in antiviral therapy: what is accepted treatment now?
    McHutchison JG
    J Gastroenterol Hepatol; 2002 Apr; 17(4):431-41. PubMed ID: 11982724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
    Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
    Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial results of peginterferons in combination with ribavirin.
    Craxi A; Licata A
    Semin Liver Dis; 2003; 23 Suppl 1():35-46. PubMed ID: 12934167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
    Ogurtsov PP; Kukhareva EI
    Klin Med (Mosk); 2016; 94(3):224-30. PubMed ID: 27522730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.
    Singal AG; Waljee AK; Shiffman M; Bacon BR; Schoenfeld PS
    Aliment Pharmacol Ther; 2010 Oct; 32(8):969-83. PubMed ID: 20937042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hepatitis C: critical appraisal of the evidence.
    Cammà C; Licata A; Cabibbo G; Latteri F; Craxì A
    Expert Opin Pharmacother; 2005 Mar; 6(3):399-408. PubMed ID: 15794731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
    Taliani G; Gemignani G; Ferrari C; Aceti A; Bartolozzi D; Blanc PL; Capanni M; Esperti F; Forte P; Guadagnino V; Mari T; Marino N; Milani S; Pasquazzi C; Rosina F; Tacconi D; Toti M; Zignego AL; Messerini L; Stroffolini T;
    Gastroenterology; 2006 Apr; 130(4):1098-106. PubMed ID: 16618404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
    Scott LJ; Perry CM
    Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of pegylated interferon α-2b and ribavirin in chronic hepatitis C virus (genotypes 1 and 4) infection.
    Wiśniewska-Ligier M; Pawłowska M; Pilarczyk M; Halota W; Woźniakowska-Gęsicka T
    J Pediatr Gastroenterol Nutr; 2013 Dec; 57(6):694-9. PubMed ID: 23942001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load.
    Tamai H; Mori Y; Shingaki N; Kawashima A; Tsukuda H; Higashi K; Moribata K; Kawaguchi M; Ueda K; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Ichinose M
    Antivir Ther; 2014; 19(1):107-15. PubMed ID: 24162072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe.
    Husa P; Oltman M; Ivanovski L; Rehák V; Messinger D; Tietz A; Urbanek P
    Eur J Gastroenterol Hepatol; 2011 May; 23(5):375-81. PubMed ID: 21502923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyethylene glycol-interferon: current status in hepatitis C virus therapy.
    Wedemeyer H; Wiegand J; Cornberg M; Manns MP
    J Gastroenterol Hepatol; 2002 Dec; 17 Suppl 3():S344-50. PubMed ID: 12472962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Moreno L; Quereda C; Moreno A; Perez-Elías MJ; Antela A; Casado JL; Dronda F; Mateos ML; Bárcena R; Moreno S
    AIDS; 2004 Jan; 18(1):67-73. PubMed ID: 15090831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
    Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R
    Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
    Gheorghe L; Grigorescu M; Iacob S; Damian D; Gheorghe C; Iacob R; Simionov I; Vadan R; Parvulescu I; Bancila I
    Rom J Gastroenterol; 2005 Jun; 14(2):109-15. PubMed ID: 15990928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.